ThermoGenesis Holdings (THMO)
OTHER OTC:THMO
Top Page
No summary available
Positive Factors
Business Model Strength
ThermoGenesis's focus on automated cell processing technologies positions it well in the growing regenerative medicine field, offering potential for long-term revenue growth as demand for efficient cell therapy solutions increases.
Negative Factors
Financial Instability
Negative equity indicates a precarious financial position, raising concerns about the company's solvency and ability to sustain operations without restructuring or additional capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Business Model Strength
ThermoGenesis's focus on automated cell processing technologies positions it well in the growing regenerative medicine field, offering potential for long-term revenue growth as demand for efficient cell therapy solutions increases.
Read all positive factors
ThermoGenesis Holdings (THMO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.58K
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)60.04
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,847,517
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.85
Price to Sales (P/S)0.15
P/FCF Ratio-0.26
Enterprise Value/Market Cap5.40K
Enterprise Value/Revenue0.89
Enterprise Value/Gross Profit4.22
Enterprise Value/Ebitda-1.23
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ThermoGenesis Holdings Business Overview & Revenue Model
Company Description
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally...
How the Company Makes Money
ThermoGenesis Holdings generates revenue through the sale of its bioprocessing and cell therapy equipment, including automated cell separation systems and cryopreservation solutions. The company also earns income from licensing its proprietary tec...
ThermoGenesis Holdings Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.61M | 9.45M | 10.48M | 9.29M | 9.74M | 13.05M |
| Gross Profit | 2.03M | 1.93M | 2.71M | 3.49M | 1.26M | 5.70M |
| EBITDA | -6.94M | -7.74M | -5.27M | -5.14M | -8.16M | -4.81M |
| Net Income | -14.74M | -17.98M | -11.27M | -11.38M | -16.35M | -9.50M |
Balance Sheet | ||||||
| Total Assets | 10.09M | 11.23M | 19.39M | 20.65M | 20.86M | 15.21M |
| Cash, Cash Equivalents and Short-Term Investments | 1.18M | 2.00M | 4.18M | 7.28M | 7.16M | 3.16M |
| Total Debt | 6.93M | 10.56M | 10.37M | 10.46M | 7.68M | 5.69M |
| Total Liabilities | 11.17M | 14.82M | 16.06M | 17.25M | 14.99M | 14.30M |
| Stockholders Equity | 975.00K | -1.67M | 4.30M | 3.83M | 5.80M | 386.00K |
Cash Flow | ||||||
| Free Cash Flow | -4.59M | -5.45M | -7.68M | -6.71M | -14.42M | -3.44M |
| Operating Cash Flow | -3.61M | -3.72M | -7.28M | -6.62M | -14.39M | -3.26M |
| Investing Cash Flow | -982.00K | -1.73M | -400.00K | -93.00K | -23.00K | -182.00K |
| Financing Cash Flow | -82.00K | 3.28M | 4.59M | 6.83M | 17.42M | 4.20M |
ThermoGenesis Holdings Risk Analysis
ThermoGenesis Holdings disclosed 46 risk factors in its most recent earnings report. ThermoGenesis Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ThermoGenesis Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $1.58K | ― | ― | ― | ― | ― | |
52 Neutral | $18.14M | -382.08 | -647.90% | ― | -44.57% | 55.97% | |
45 Neutral | $2.93M | -0.28 | -191.39% | ― | ― | 76.53% | |
44 Neutral | $2.32M | -115.09 | -173.74% | ― | 82.96% | 82.04% | |
44 Neutral | $1.99M | -0.18 | -145.52% | ― | ― | 97.70% | |
40 Underperform | $7.17M | -1.29 | -220.42% | ― | -41.03% | 35.71% |
* Healthcare Sector Average
THMO
ThermoGenesis Holdings
―
―
―
AEMD
Aethlon Medical
2.23
-24.97
-91.80%
VTAK
Catheter Precision
0.86
-5.03
-85.37%
MOVE
Movano
11.05
5.23
89.96%
BJDX
Bluejay Diagnostics
2.05
-8.27
-80.14%
HSCS
Heart Test Laboratories, Inc.
2.25
-1.25
-35.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―